Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07349394 · ClinicalTrials.gov registry record · Phase 1
Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants
A Phase 1 study of Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT07349394: Active Phase 1 study of Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated.
NCT07349394 is a Phase 1 study of Cystic Fibrosis that is active but no longer recruiting, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 18 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07349394, a Phase 1 study of Cystic Fibrosis, is active but no longer recruiting, sponsored by Vertex Pharmaceuticals Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with rosuvastatin.
Conditions Studied
Interventions
- DRUG Rosuvastatin
- DRUG VNZ/TEZ/D-IVA
Study Locations (1)
Kansas
- Altasciences - Kansas City - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-01-12 |
| Est. Completion | 2026-04-04 |
| Phase | Phase 1 |
What the registry record for NCT07349394 still lists
NCT07349394 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Rosuvastatin is the first listed.
NCT07349394 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT07349394 about?
NCT07349394 is a clinical study titled "Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants". The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with rosuvastatin.
What is the current status of trial NCT07349394?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-01-12. Estimated completion is 2026-04-04.
What conditions does trial NCT07349394 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT07349394?
The interventions under investigation include: Rosuvastatin (DRUG), VNZ/TEZ/D-IVA (DRUG).
Who is sponsoring clinical trial NCT07349394?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07349394 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07349394's enrollment target sits among peer trials
18 135th of 169 higher than 33 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RECRUITING · Phase 1
-
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
RECRUITING · Phase 1
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI